Welcome to the healthcare professional section of Sycrest.co.uk


Sycrest (asenapine) is the first tetracyclic antipsychotic therapy for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.

Sycrest

Sycrest is the first tetracyclic antipsychotic with a unique receptor profile:

  • Sycrest demonstrates rapid efficacy as early as day 23
  • Treatment response with Sycrest can be predicted early10
  • Sycrest demonstrates sustained efficacy at 12 weeks 7
  • Sycrest has a lower potential for long term weight gain and a lower impact on metabolic profile compared to olanzapine8

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Lundbeck Limited, Medical Information, on: 01908 638972.

UK/SYC/1212/0283
Last updated December 2012